ARTELO BIOSCIENCES, INC.

ARTL Nasdaq CIK: 0001621221

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation NV
Business Address 505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA, 92075
Mailing Address 505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA, 92075
Phone 858-925-7049
Fiscal Year End 1231
EIN 331220924

Financial Overview

FY2025

$600K
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G Passive beneficial ownership (>5%) April 3, 2026 View on SEC
8-K Current report of material events March 30, 2026 View on SEC
8-K Current report of material events March 26, 2026 View on SEC
S-1/A IPO registration amendment March 24, 2026 View on SEC
S-1 IPO registration statement March 24, 2026 View on SEC
S-1/A IPO registration amendment March 23, 2026 View on SEC
S-1 IPO registration statement March 20, 2026 View on SEC
8-K Current report of material events March 18, 2026 View on SEC
8-K Current report of material events March 17, 2026 View on SEC
8-K Current report of material events March 6, 2026 View on SEC

Material Events

8-K Strategy Change March 17, 2026
High Impact
  • Aims to meet NASDAQ listing requirements and avoid delisting.
  • Intends to improve market perception and attract a broader range of investors, including institutional funds.
View Analysis
8-K Strategy Change March 6, 2026
High Impact
  • Aims to improve stock's market standing and liquidity.
  • Seeks to regain and maintain compliance with Nasdaq's $1.00 minimum bid price requirement.
View Analysis
8-K Financial Distress February 5, 2026
High Impact
  • ARTELO secured a vital Nasdaq listing extension, preventing immediate delisting and preserving trading accessibility.
  • The company has until March 30, 2026, to regain compliance with Nasdaq's financial standards, providing a defined timeframe.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.